| Discovery | Phase 1 | Phase 2 | Phase 3 | Marketed |
|---|
JNJ42756493 (erdafitinib)
FGFr inhibitor (Oncology)
| . | . | . |
Partner: 
Mechanism of Action: Fibroblast growth factor receptor (FGFr) inhibition
Indication: Oncology
Discovery: Investigational compound JNJ42756493 (erdafitinib), was discovered in collaboration with Janssen Pharmaceutica, N.V. from a partnership which commenced in June 2008. Astex’s FGFr inhibitor program originated from a collaboration initiated in 2005 with the Cancer Research UK Drug Discovery Group at the Newcastle Cancer Centre (Newcastle University UK), and Cancer Research Technology Limited.
How this therapy can help
Activating mutations, amplifications and over-expression of FGFs have been implicated in the pathogenesis of a variety of human tumors including breast, prostate, colon and bladder cancers. Inhibition of FGFrs is expected to restore control of proliferative processes driven by these aberrations.
Clinical status
JNJ42756493 is currently being evaluated by Janssen in Phase 2 and Phase 3 clinical trials in patients with advanced urothelial cancer. Erdafitinib is also being evaluated in Phase 1 and Phase 2 clinical trials in patients with advanced hepatocellular carcinoma, advanced non-small lung cancer, esophageal cancer or cholangiocarcinoma. In March 2018, erdafititinib received Breakthrough Therapy Designation in the treatment of urothelial cancer from the US Food and Drug Administration (FDA).